{"search_session":{},"preferences":{"l":"en","queryLanguage":"en"},"patentId":"EP_1167975_A1","frontPageModel":{"patentViewModel":{"ref":{"entityRefId":"105-922-798-580-321","entityRefType":"PATENT"},"entityMetadata":{"linkedIds":{"empty":true},"tags":[],"collections":[{"id":11739,"type":"PATENT","title":"University of Paris Descartes (Paris 5) - Patent Portfolio","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":1877,"tags":[],"user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"notes":[{"id":8379,"type":"COLLECTION","user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"text":"
Search Applicants and Owners separately: uni* AND Paris Descar*; uni* AND Descar*. Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 1543
Search Applicants and Owners separately: uni* AND Paris Descar*; uni* AND Descar*. Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 1543
- obtaining total RNAs of a tumor cell or sample or biological fluid (blood, plasma, urine...)
- cDNA synthesis by reverse transcription
- PCR (polymerase chain reaction) amplification of CGA cDNA in the presence of oligonucleotide primers specific for CGA gene,
- Detection (or quantitation) of PCR product by measuring the increase in fluorescence by using a fluorescent double-stranded DNA-binding dye or by subsequent contact of a specific labelled nucleic acid probe to the CGA PCR products."],"number":12,"annotation":false,"claim":true,"title":false},{"lines":["The method of any one of claims 3 to 12, wherein CGA overexpression is indicative of endocrine treatment responsiveness of said tumor or subject."],"number":13,"annotation":false,"claim":true,"title":false},{"lines":["The method of any one of claims 8 to 12, wherein the presence of CGA mRNAs in the tumor cell or tissue sample above an average value calculated from non-tumoral sample is indicative of endocrine treatment-responsiveness."],"number":14,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 14, wherein a two-fold increase, preferably a five-fold increase, is indicative of endocrine responsiveness."],"number":15,"annotation":false,"claim":true,"title":false},{"lines":["A method of predicting endocrine treatment responsiveness of a subject with a tumor, comprising assessing in vitro or ex vivo the ERα status and the CGA status of said tumor or subject."],"number":16,"annotation":false,"claim":true,"title":false},{"lines":["The method of any one of the preceding claims, wherein the tumor is a hormone-associated tumor, more preferably a hormone-dependent tumor, even more preferably a breast tumor or a prostate tumor."],"number":17,"annotation":false,"claim":true,"title":false},{"lines":["A method of predicting the responsive to antiestrogens (Tamoxifen, Raloxifen, Droloxifen, Tonemifen...) for a subject with breast tumor, comprising assessing in vitro or ex vivo the CGA status of the subject or tumor."],"number":18,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 18, wherein an increase in CGA expression over a reference value is indicative of a responsiveness to tamoxifen."],"number":19,"annotation":false,"claim":true,"title":false},{"lines":["The use of a CGA gene product as a marker of endocrine responsiveness of a tumor or tumor cell."],"number":20,"annotation":false,"claim":true,"title":false},{"lines":["A kit for implementing a method according to any one of claims 1 to 19, comprising reagents for assessing the CGA gene status in a sample."],"number":21,"annotation":false,"claim":true,"title":false},{"lines":["A nucleic acid array comprising a plurality of nucleic acids attached to a support, wherein at least one or a portion of said nucleic acids are complementary to a region of the CGA gene or mRNA."],"number":22,"annotation":false,"claim":true,"title":false},{"lines":["A method of selecting a patient with a tumor, for endocrine treatment, comprising assessing the CGA status of said patient or tumor."],"number":23,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 23, wherein the tumor is a breast tumor."],"number":24,"annotation":false,"claim":true,"title":false},{"lines":["A method of detecting breast cancer in a subject, comprising detecting in vitro or ex vivo a CGA expression product in a breast cell, tissue sample or biological fluids of the subject."],"number":25,"annotation":false,"claim":true,"title":false},{"lines":["A method of detecting breast cancer in a subject, comprising detecting in vitro or ex vivo CGA protein in a breast cell or sample or in a biological fluid of the subject."],"number":26,"annotation":false,"claim":true,"title":false},{"lines":["A method of selecting or identifying compounds that modulate CGA expression or activity, comprising contacting a cell expressing a CGA gene with a candidate compound and selecting or identifying the cell(s) having a modified CGA status."],"number":27,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 27, to select or identify an inhibitor of CGA gene expression or activity."],"number":28,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 27, to select or identify an activator of CGA gene expression or activity."],"number":29,"annotation":false,"claim":true,"title":false},{"lines":["The use of a compound that modulates CGA expression or activity for the manufacture of a medicament for the treatment of a hormone-associated tumor or tumor cell."],"number":30,"annotation":false,"claim":true,"title":false},{"lines":["The use of claim 30, for reducing or arresting the growth or development of a hormone associate tumor or tumor cell, more particularly of breast or prostate tumor."],"number":31,"annotation":false,"claim":true,"title":false},{"lines":["The use of a compound that modulates CGA expression or activity for the manufacture of a medicament for inducing or stimulating the endocrine responsiveness of a tumor or tumor cell."],"number":32,"annotation":false,"claim":true,"title":false},{"lines":["The use of a nucleic acid encoding a CGA polypeptide, for the manufacture of a medicament for the treatment of a hormone-associated tumor or tumor cell or for inducing or stimulating the endocrine responsiveness of a tumor or tumor cell."],"number":33,"annotation":false,"claim":true,"title":false}]}},"filters":{"npl":[],"notNpl":[],"applicant":[],"notApplicant":[],"inventor":[],"notInventor":[],"owner":[],"notOwner":[],"tags":[],"dates":[],"types":[],"notTypes":[],"j":[],"notJ":[],"fj":[],"notFj":[],"classIpcr":[],"notClassIpcr":[],"classNat":[],"notClassNat":[],"classCpc":[],"notClassCpc":[],"so":[],"notSo":[],"sat":[]},"sequenceFilters":{"s":"SEQIDNO","d":"ASCENDING","p":0,"n":10,"sp":[],"si":[],"len":[],"t":[],"loc":[]}}